報價延遲最少15分鐘:2025/01/21 08:55 EST
|
|
|
|
|
||||||||||||
|
|
|
|
|
-- 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
5.87/4.45
|
|
企業價值
20.71B
|
| 資產負債 |
|
每股賬面淨值
15.94
|
| 現金流量 |
|
現金流量率
0.02
|
| 損益表 |
|
收益
1.70B
|
|
每股收益
22.20
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2025/01/21 08:55 EST
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device and that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the U.S. Food and Drug Administration in 2005, approximately 425,000 insulin-dependent diabetics are using it worldwide. |